Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News

Emmaus Life Sciences, Inc.

OTC: EMMA · Life Sciences · 2 alerts · CIK 822370

Share price
$0.0320Close, Nov 20
Market cap
$2.25M
Shares outstanding
70.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: price from the latest market close, market cap from Nasdaq's listing data (else SEC cover-page shares × price), shares from the latest SEC cover page. Not a valuation or a recommendation. All Emmaus Life Sciences, Inc. filings on SEC EDGAR ↗

6:03 AM ET 8-K
Financial Results

Emmaus Life Sciences Financial Results

Emmaus Life Sciences reported Q3 2026 net revenues of $1.9 million, a decline from $3.4 million in the prior year period, primarily due to a 44% decrease in U.S. revenues following a licensing agreement with NeoImmuneTech. The company realized a net loss of $4.7 million for the quarter, impacted by lower direct sales of Endari and an increase in other expenses related to the fair value of conversion features.

Term
Q3 2026

“Our global net revenues declined for the three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as our licensing agreement with NeoImmuneTech Inc. (NIT), became effective on May 15, 2026.”

Willis Lee, Chairman and Chief Executive Officer

“The decline was partially offset by a related reduction in our operating expenses. Management believes that the conflict in the Midde East also adversely affected net revenues in the region,”

Willis Lee, Chairman and Chief Executive Officer
6:03 AM ET 10-Q
Financial Results

Emmaus Life Sciences Q3 2026 Results: Net Loss of $4.74M, Loss Widens

Emmaus Life Sciences reported a net loss of $6.7 million for the nine months ended September 30, 2026, compared to a $5.5 million loss in the prior year period, despite a 18.5% increase in net revenues to $10.2 million. The company's financial position remains constrained with a total stockholders' deficit of $68.7 million and cash and cash equivalents of only $0.97 million as of the reporting date.

Key figure
Net loss $4.74M

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.